326P - Transition of recurrence-free survival for early-stage breast cancer at National Cancer Center Hospital East

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Breast Cancer
Presenter Motoko Kaneko
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors M. Kaneko1, A. Hosono2, M. Sasaki3, N. Matsubara4, Y. Naito4, S. Saito1, T. Yamanaka5, N. Wada6, H. Mukai4
  • 1Pharmacy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2Pediatric Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 3Breast And Medical Oncology, National Cancer Center Hospital East, Kahiwa/JP
  • 4Breast And Medical Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 5Exploratory Oncology Research And Clinical Trial Center, National Cancer Center Hospital East, Kashiwa/JP
  • 6Breast Surgery, National Cancer Center Hospital East, Kashiwa/JP

Abstract

Aim

The prognosis for breast cancer has recently been improved by the development of numerous, active chemotherapeutic regimens and hormone therapies. Some reports from the United States and Europe have described improved prognoses for recurrent breast cancer. This study investigated how recurrence-free survival (RFS) after complete resection has improved over time for women with early-stage breast cancer treated at our institute.

Methods

We retrospectively analyzed RFS in 2,958 female patients with primary breast cancer who underwent complete resection between July 1992 and December 2010 at National Cancer Center Hospital East in Japan. Medical records were reviewed to obtain patient background, treatment for the initial disease, and RFS as estimated using the Kaplan-Meier product-limit method. The primary outcome was to evaluate the association between the year of treatment and subsequent RFS.

Results

Patients were divided into the following four groups according to the year of surgery: 1992-1997; 1998-2001; 2002-2006; and 2007-2010. A significant improvement was seen in RFS across the four groups, with more recent groups showing longer RFS (P < 0.001), and 5-year RFS rates were 79.6%, 80.7%, 84.7%, and 89.3%. Analyses by tumor subtype showed significant improvements in RFS for hormone receptor-positive tumors (P < 0.001), but not for HER2-positive (P = 0.382) or triple-negative tumors (P = 0.108).

Conclusions

For these groups of patients, our study shows that RFS for early-stage breast cancer after complete resection improved between 1992 and 2010.

Disclosure

All authors have declared no conflicts of interest.